Equities analysts expect that Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will report earnings of ($0.62) per share for the current quarter, according to Zacks. Three analysts have made estimates for Bellicum Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.75) and the highest estimate coming in at ($0.55). Bellicum Pharmaceuticals posted earnings of ($0.74) per share during the same quarter last year, which would suggest a positive year over year growth rate of 16.2%. The business is scheduled to report its next earnings results on Tuesday, August 14th.
On average, analysts expect that Bellicum Pharmaceuticals will report full year earnings of ($2.52) per share for the current year, with EPS estimates ranging from ($2.93) to ($2.22). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.50) per share, with EPS estimates ranging from ($3.33) to ($1.93). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.02. The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.08 million.
BLCM has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 9th. BidaskClub raised shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, April 17th. SunTrust Banks cut their target price on shares of Bellicum Pharmaceuticals to $18.00 and set a “buy” rating for the company in a research note on Wednesday, January 31st. Citigroup increased their target price on shares of Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the company a “hold” rating in a research note on Friday, February 16th. Finally, Zacks Investment Research lowered shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. Bellicum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $17.98.
Hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. lifted its stake in Bellicum Pharmaceuticals by 47.1% during the third quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock valued at $1,516,000 after purchasing an additional 41,995 shares during the last quarter. Virtus Fund Advisers LLC acquired a new stake in Bellicum Pharmaceuticals during the fourth quarter valued at approximately $343,000. X Square Capital LLC acquired a new stake in Bellicum Pharmaceuticals during the fourth quarter valued at approximately $544,000. Prosight Management LP acquired a new stake in Bellicum Pharmaceuticals during the fourth quarter valued at approximately $2,534,000. Finally, Vident Investment Advisory LLC lifted its stake in Bellicum Pharmaceuticals by 37.2% during the fourth quarter. Vident Investment Advisory LLC now owns 150,426 shares of the biopharmaceutical company’s stock valued at $1,265,000 after purchasing an additional 40,780 shares during the last quarter. 54.41% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:BLCM traded up $0.01 during trading on Thursday, reaching $8.00. The company had a trading volume of 411,997 shares, compared to its average volume of 880,611. The firm has a market cap of $342.98 million, a P/E ratio of -2.82 and a beta of 0.46. Bellicum Pharmaceuticals has a twelve month low of $5.02 and a twelve month high of $14.49. The company has a current ratio of 6.75, a quick ratio of 6.75 and a debt-to-equity ratio of 0.53.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.